It is possible that recombinant activated factor VII (rFVIIa) could revolutionise the medical and surgical management of haemorrhage following trauma and surgery due to its ease of administration and mechanism of action. This article reviews the evidence for the use of rFVIIa as a pro-coagulant, its mechanism of action, safety and recent research into its use in blunt and penetrating trauma and haemorrhage. The potential role of rFVIIa, both in the pre-hospital environment and in the emergency room or operating theatre, is discussed. Administration of rFVIIa at the roadside, on the battlefield or in trauma centre may have significant potential implications, especially for the paramedical and surgical teams and even for strategic planners. Finally, the areas where further research is needed to provide objective evidence of its efficacy are elaborated. The potential thromboembolic complications of systemic administration of rFVIIa need to be carefully monitored but the high cost of this drug is likely to be the limiting factor in its widespread use.
HednerURecombinant coagulation factor VIIa; from the concept to clinical application in haemophilia treatment in 2000. Semin Thromb Hemost2000; 26: 363–366.
2.
LusherJMRecombinant factor VIIa (NovoSevenrG) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis1996;26:124–130.
3.
LusherJMRecombinant activated factor VII for the treatment of intramuscular haemorrhages: A comparison of early versus late treatment. Blood Coagul Fibrinolysis1998;9:S111–S114.
4.
LusherJMAcute haemarthroses: The benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis2000;11:S45–S49.
5.
HednerUTreatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost1999;82:531–539.
6.
HednerUGlazerSPingelKAlbertsKABlombackMSchulmanSJohnssonHSuccessful use of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost1996;76:200–204.
7.
IngerslevJFreidmanDGastineauDGilchristGJohnssonHLucasGMcPhersonJJPrestonEScheibelESchumanMMajor surgery in haemophiliac patients with inhibitors using recombinant factor VIIa. Haemostasis1996;26:118–123.
8.
ShapiroADGilchristGSHootsWKCooperHAGastineauDAProspective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost1998;19:163–176.
9.
RobertsHClinical experience with recombinant factor VIIa (NovoSevenrG): Summary of efficacy and safety. Haemophilia1996;2:63.
10.
MarianiGTestaMGDi PaolantonioT.: Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang1999;77:131–136.
11.
HunaultMBauerKARecombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost2000;26:401–405.
12.
LissitchkovTZarkovaAKalevIRecombinant factor VIIa (NovoSeven): A universal haemostatic agent? Haemophilia2000;6:348.
13.
FriederichPWWeverPCBrietEDoorenbosCJLeviMSuccessful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Haematol2001;66:292–294.
14.
KristensenJKillanderAHippeEHellebergCEllegardJHolmMKuttiJMellqvistU-HJohanssonJEGlazerSHednerUClinical experience with recombinant factor VIIa in patients with thrombocytopaenia. Haemostasis1996;26:159–164.
15.
GerotziafasGTZervasCGavrielidisGTokmaktsisAHatjiharissiEPapaioannuMLazaridouAConstantinouNSamamaMMChristakisJEffective haemostasis with rFVIIa treatment in two patients with severe thrombocytopaenia and life threatening haemorrhage. Am J Haematol2002;69:219–222.
16.
PoonMCDemersCJobinFWuJWRecombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood1999;94:3951–3953.
17.
TengbornLPetrusonBA patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost1996;75:981–982.
18.
PetersMHeijboerHTreatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost1998;80:352.
19.
ChaunsumritATreepongkarunaSPhuapraditPSuccessful invasive procedures in children with liver failure using recombinant factor VIIa. Haemophilia2000;6:348.
20.
LismanTLeebeekFWMeijerKvan der MeerJNieuwenhuisHKDe GrootPRecombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology2002;35:616–621.
21.
HednerUNovoSevenrG as a universal haemostatic agent. Blood Coagul Fibrinolysis2000;11:S107–S111.
22.
GallistlSCvirnGMunteanWRecombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost1999;81:245–249.
23.
MorriseyJHTissue factor and factor VII initiation of coagulation. In: Haemostasis and Thrombosis, Basic Principles Clinical Practice, 4th ed. Eds ColmanRWHirshJMarderVJClowesAWGeorgeJN. Lippincott Willams & WilkinsPhiladelphia, PA, USA2001 pp. 89–101.
24.
ErhardtsenEPharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost2000;26:385–391.
25.
RapaportSIRaoLVThe tissue factor pathway: How it became a ‘prima ballerina’. Thromb Haemost1995;74:7–17.
26.
MonroeDMHoffmanMAllenGARobertsHRThe factor VII-platelet interplay: Effectiveness of the recombinant factor VIIa in the treatment of bleeding in severe thrombocytopaenia. Semin Thromb Haemost2000;26:373–377.
27.
MonroeDMHoffmanMOliverJARobertsHRPlatelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol1997;99:542–547.
28.
MonroeDMHoffmanMOliverJARobertsHRA possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis.1998; 9 (Suppl 1):S15–S20.
29.
OliverJAMonroeDMRobertsHRHoffmanMThrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol1999;19:170–177.
30.
SteinSFDuncanACutlerGlazer SDisseminated intravascular coagulation (DIC) in a haemophiliac treated with recombinant factor VIIa (abstract). Blood1990;76:438a.
31.
RobertsHRClinical experience with activated factor VII: Focus on safety aspects. Blood Coagul Fibrinolysis.1998; 9 (Suppl 1):S115–S118.
32.
van der PlankenMGSchroyensWVertessenFMichielsJJBernemanZNDistal deep vein thrombosis in a haemophilia patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion. Blood Coagul Fibrinolysis2002;13:367–370.
33.
VlotAJTonEMacKaayAJKramerMHGaillardCATreatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med2000;108:421–423.
34.
WhiteBMcHaleJRaviNReynoldsJStephensRMoriartyJSmithOPSuccessful use of recombinant FVIIa (NovosevenrG) in the management of intractable post-surgical *intra-abdominal haemorrhage. Br J Haematol1999;107:677–678.
35.
LaffanMACumminsMRecombinant factor VIIa for intractable surgical bleeding. (Abstract) Blood2000;96(11):85b.
36.
EjlersenEMelsenTIngerslevJAndreasenRBVilstrupHRecombinant activated factor VII (rFVIIa) acutely normalises prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand Gastroenterol2001;36:1081–1085.
37.
FriederichPWGeerdinkMGSpataroMMesselinkEJHennyCPBullerHRLeviMThe effect of the administration of recombinant activated factor VII (NovoSevenrG) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Blood Coagul Fibrinolysis2000;11:S129–S132.
38.
Al DouriMShaftiTKhudairiDAl BokhariEBlackLAkinwaleMOsmanMusa MAl HomaidhiAAl FagihMAndreasenRBEffect of administration of recombinant factor VII (rFVIIa; NovoSevenrG) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis2000;11:S121–S127.
39.
LiemAKSEBiesmaDHErnstSMPGSchepensMAAMRecombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb Heamost1999;82:150–151.
40.
PickardJDKirkpatrickPJMelsenTAndreasenRBGellingLFryerTMatthewsJMinhasPHutchinsonPJAMenonDDowneySPKendallIClarkJCarpenterTAWilliamsEPerssonLPotential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis2000;11:S117–S120.
41.
ChuansumritAChantarojanasiriTIsarangkuraPTeeraratkulSHongengSHathiratPRecombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis2000;11:S101–S105.
42.
KenetGWaldenREldadAMartinowitzUTreatment of traumatic bleeding with recombinant factor VIIa. Lancet1999;354:1879.
43.
O'NeillPABluthMGlosterEWaliDPriovolosSDiMaioTMEssexDWCantaneseCAStraussRASuccessful use of recombinant activated factor VII for trauma-associated haemorrhage in a patient without preexisting coagulopathy. J Trauma2002;52:400–405.
44.
MartinowitzUHolcombJBPusateriAESteinMOnacaNFreidmanMMacAitisJMCastelDHednerUHessJRIntravenous rFVIIa administered for haemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma2001;50:721–729.
45.
LynnMJerokhimovIJewelewiczDPopkinCJohnsonEWRashidQNBrownMMartinowitzUCohnSMEarly use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental haemorrhagic shock: A pilot study. J Trauma2002;52:703–707.
46.
SchreiberMAHolcombJBHednerUBrundageSIMacAitisJMHootsKThe effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma2002;53:252–259.
47.
JeroukhimovIJewelewiczDZaiasJHensleyGMacLeodJCohnSMRashidQPernasFLedfordMRGomez-FeinELynnMEarly injection of high dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma2002;53:1053–1057.
48.
SondeenJLPusateriAEYantisLDHolcombJBHednerURecombinant factor VIIa strengthens the clot in uncontrolled haemorrhage: Potential advance in combat casualty care for the treatment of non-compressible injuries. J Surg Res In press.
49.
SapsfordWKirkmanEWattsSKenwardCCooperGJIntravenous Recombinant Activated Factor VII Improves Survival in a Pig Model of Uncontrolled Haemorrhage from an Aortotomy. Presented at the Advanced Technology Applications in Combat Casualty Care (ATACCC) Conference2003 St Pete Beach, Fl, USA.
50.
HongMeng ZWolbergASMonroeDMHoffmanMThe effect of temperature and pH on the activity of factor VIIa: Implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma2003;55:886–891.
51.
MartinowitzUKenetGSegalELuboshitzJLubetskyAIngerslevJLynnMRecombinant activated factor VII for adjunctive haemorrhage control in trauma. J Trauma2001;51:431–439.
52.
BowleyDMGBarkerPBoffardKDDamage control surgery — Concepts and practice. J R Army Med Corps2000;146:176–182.
53.
MacKenzieEJFowlerCJEpidemiology. In: Trauma. 4th ed.MattoxKLFelicianoDVMooreEE. McGraw-HillNew York, NY, USA2000 pp. 21–39.
54.
SauaiaAMooreFAMooreEE.: Epidemiology of trauma deaths: A reassessment. J Trauma1995;38:185–193.
55.
BellamyRFThe causes of death in conventional land warfare: Implications for combat casualty care research. Mil Med1984;149:55–62.
56.
Prehospital Trauma Life Support Committee of the National Association of Emergency Medical Technicians in Cooperation with the Committee on Trauma of the American College of Surgeons: Shock and fluid resuscitation. In: PHTLS Basic and Advanced Prehospital Trauma LifeSupport 4th ed.Mosby, St Louis, MO, USA1999 pp. 136–157.
57.
American College of Surgeons Committee on Trauma: Shock assessment and management. In: Advanced Trauma Life Support for Doctors Student Course Manual6th ed.American College of SurgeonsChicago, IL, USA1997 pp. 87–107.
58.
Director General Army Medical Services: Shock. In: Battlefield Advanced Trauma Life Support2nd ed.The British ArmyUK2000 pp. 5–14.
